Free Trial

Neurocrine Biosciences (NBIX) News Today

Neurocrine Biosciences logo
$120.27 +1.49 (+1.25%)
As of 05/15/2025 04:00 PM Eastern

NBIX Latest News

Neurocrine Biosciences, Inc. stock logo
Lighthouse Investment Partners LLC Makes New $2.05 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Lighthouse Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,000 shares of the company's stock, valued a
Neurocrine Biosciences, Inc. stock logo
Jacobs Levy Equity Management Inc. Sells 456,979 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Jacobs Levy Equity Management Inc. lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 87.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,189 sha
Neurocrine Biosciences, Inc. stock logo
Focus Partners Wealth Purchases 4,420 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Focus Partners Wealth boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,078 shares of the company's stock after acquiring an
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Orbimed Advisors LLC
Orbimed Advisors LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 210.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 938,120 shares of the company's stock aft
Neurocrine Biosciences, Inc. stock logo
Hudson Bay Capital Management LP Trims Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Hudson Bay Capital Management LP lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 24.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,342 shares of the company's stock after selling 9,658
Neurocrine Biosciences, Inc. stock logo
Deutsche Bank AG Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Deutsche Bank AG grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 461,782 shares of the company's stock after acquiring an additional 23,951 shares
Neurocrine Biosciences, Inc. stock logo
Bank of America Corp DE Cuts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Bank of America Corp DE decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,034 shares of the company
Neurocrine Biosciences, Inc. stock logo
Integral Health Asset Management LLC Invests $21.84 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Integral Health Asset Management LLC acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 160,000 shares of the company'
Neurocrine Biosciences, Inc. stock logo
Iron Triangle Partners LP Invests $43.43 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Iron Triangle Partners LP purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 318,195 shares of the company's stock, valued at app
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Ameriprise Financial Inc.
Ameriprise Financial Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 413,479 shares of the company's stock
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Driehaus Capital Management LLC
Driehaus Capital Management LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,921 shares of the company's stock after acquiring an add
Neurocrine Biosciences, Inc. stock logo
Research Analysts Issue Forecasts for NBIX Q2 Earnings
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report released on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings per
Neurocrine Biosciences, Inc. stock logo
Research Analysts Offer Predictions for NBIX Q2 Earnings
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at William Blair boosted their Q2 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipat
Neurocrine Biosciences, Inc. stock logo
Baird Financial Group Inc. Buys 24,657 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Baird Financial Group Inc. boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 82.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,717 shares of the company's stock after buying an
Neurocrine Biosciences, Inc. stock logo
Mercer Global Advisors Inc. ADV Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Mercer Global Advisors Inc. ADV raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 52.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,112 shares of the company's stock after purcha
Q2 EPS Forecast for Neurocrine Biosciences Lifted by Analyst
Neurocrine Biosciences, Inc. stock logo
Wedbush Has Negative Forecast for NBIX Q1 Earnings
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Wedbush decreased their Q1 2026 EPS estimates for shares of Neurocrine Biosciences in a report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.10 per share for the
Neurocrine Biosciences, Inc. stock logo
Cantor Fitzgerald Issues Positive Outlook for NBIX Earnings
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for Neurocrine Biosciences in a report released on Tuesday, May 6th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of $4.39 for the
Neurocrine Biosciences, Inc. stock logo
What is Leerink Partnrs' Forecast for NBIX FY2025 Earnings?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Neurocrine Biosciences in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earn
Neurocrine Biosciences, Inc. stock logo
What is William Blair's Forecast for NBIX FY2025 Earnings?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the company
Neurocrine Biosciences, Inc. stock logo
HC Wainwright Issues Positive Forecast for NBIX Earnings
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for Neurocrine Biosciences in a research note issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.
Neurocrine Biosciences, Inc. stock logo
Deerfield Management Company L.P. Series C Sells 454,590 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Deerfield Management Company L.P. Series C lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 862,000 shares of the company's stock after selling 454,590 sh
Neurocrine Biosciences, Inc. stock logo
BNP Paribas Financial Markets Has $39.56 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
BNP Paribas Financial Markets cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 45.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,840 shares of the company's
Neurocrine Biosciences, Inc. stock logo
Schonfeld Strategic Advisors LLC Has $983,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Schonfeld Strategic Advisors LLC trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,200 shares of the company's stock a
Wedbush Analysts Raise Earnings Estimates for NBIX
Neurocrine Biosciences, Inc. stock logo
Balyasny Asset Management L.P. Invests $26.58 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Balyasny Asset Management L.P. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 194,728 shares of the company's st
FY2025 EPS Estimates for NBIX Lifted by Cantor Fitzgerald
HC Wainwright Analysts Boost Earnings Estimates for NBIX
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at Wedbush
Wedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Piper Sandler Reiterates "Overweight" Rating for Neurocrine Biosciences (NASDAQ:NBIX)
Piper Sandler restated an "overweight" rating and set a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Royal Bank of Canada Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $145.00
Royal Bank of Canada increased their price target on Neurocrine Biosciences from $137.00 to $145.00 and gave the stock an "outperform" rating in a research report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $165.00
Guggenheim boosted their target price on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research note on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences (NASDAQ:NBIX) Given New $115.00 Price Target at BMO Capital Markets
BMO Capital Markets increased their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
UBS Group Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price
UBS Group lifted their target price on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the company a "buy" rating in a research report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up Following Analyst Upgrade
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up Following Analyst Upgrade
Neurocrine Biosciences, Inc. stock logo
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00
Canaccord Genuity Group increased their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
Needham & Company LLC Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock
Needham & Company LLC raised their target price on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a report on Tuesday.
Neurocrine Biosciences, Inc. stock logo
24,000 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Cercano Management LLC
Cercano Management LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 24,000 shares of the company's stock, valued at appr
Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

NBIX Media Mentions By Week

NBIX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NBIX
News Sentiment

0.88

0.79

Average
Medical
News Sentiment

NBIX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NBIX Articles
This Week

47

17

NBIX Articles
Average Week

Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NBIX) was last updated on 5/16/2025 by MarketBeat.com Staff
From Our Partners